Biofrontera Inc. (BFRI)
(Real Time Quote from BATS)
$0.95 USD
-0.04 (-4.04%)
Updated Jun 10, 2024 01:30 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Biofrontera Inc. [BFRI]
Reports for Purchase
Showing records 41 - 59 ( 59 total )
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
2Q22: Progress Across the Board, Maintains 2022 Revenue Guidance
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Releases 1H22 Revenue Range, Keeps FY2022 Revenue Guidance of 30% Up YoY
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
1Q22: Expecting Strong YoY Revenue Growth, Trials to Expand Ameluz Use
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Pre-Releases 1Q22 $9.5 to $10M Revenue Range, Beating Our $9.2M Estimate
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Covered Company Developments from Earlier the Week
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Reasons to Sit Down with These Biotech Managements at the 2022 Conference
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Ameluz-PDT Phase 3 sBCC Trial at 70% Enrollment, Should Be Full by YE22
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Prereleases 4Q21 Revenue Range of $9.1-9.2M Among Other Recent Updates
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
RhodoLED XL PDT Lamp Use Patent Allowed, 3 Tube Ameluz Trial Enrolling
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
3Q21: Ample Funding to Support Salesforce Expansion & Thus Revenue Growth
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Superior AK Therapy, Augmenting U.S. Salesforce, Other Indications Likely
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J